Cencora (NYSE:COR) FY Conference Summary Company Overview - Cencora is a global pharmaceutical services healthcare company that ships over a billion medications annually and employs 51,000 team members [2][3] - The company reported a 9% year-over-year revenue increase and a 16% increase in both adjusted operating income and adjusted diluted EPS, generating $3 billion in free cash flow [2] Core Strategic Drivers - **Digital Transformation**: Focus on optimizing business processes through advanced analytics and AI [3] - **Talent Development**: Commitment to career growth for employees [3] - **Productivity Improvement**: Continuous focus on enhancing operational efficiency [4] - **Growth-Oriented Investments**: Prioritization of investments that align with future strategies [4] Recent Developments - Cencora completed the acquisition of Retina Consultants of America and plans to accelerate the acquisition of OneOncology, which is expected to enhance the company's MSO platform [5][8] - The company announced a $1 billion investment in supply chain infrastructure through 2030, focusing on expanding capacity and cold chain logistics [6] Financial Guidance - Long-term operating income growth guidance was raised from 5%-8% to 6%-9%, and EPS guidance was increased from 8%-12% to 9%-13% [14][15] - Following the OneOncology acquisition announcement, long-term guidance was further raised to 7%-10% for operating income and 10%-14% for EPS [15] Market Position and Growth - Cencora is well-positioned in the specialty pharmaceuticals market, which is experiencing significant innovation and growth [7] - The MSO platform is expected to drive additional growth, enhancing relationships with providers and pharmaceutical manufacturers [7][23] Challenges and Opportunities - The company is monitoring potential impacts from changes in pharmaceutical pricing policies, particularly regarding WAC decreases and their effect on physician reimbursement [25][26] - Cencora has a strong strategic global sourcing department that has successfully managed gross margin dollars despite pricing pressures [27] International Segment - The international segment, which accounts for about 20% of operating income, is expected to see 5%-8% growth, with improvements anticipated in global specialty logistics and a more focused portfolio [59][60] Share Repurchase and Capital Deployment - Share repurchases have been paused due to the OneOncology acquisition, with plans to resume after prioritizing debt repayment [66] Conclusion - Cencora is focused on enhancing its pharmaceutical-centric strategy, investing in growth-oriented opportunities, and maintaining strong financial performance while navigating market challenges [10][66]

Core Viewpoint - CVS Health Corporation has shown significant performance improvement, becoming the best performer in the healthcare sector under CEO David Joyner, with a notable stock increase of nearly 77% in the previous year [1][2]. Group 1: Company Performance - CVS Health's stock increased by nearly 77% as it recovered under the leadership of new CEO David Joyner [1]. - The company has laid out bullish long-term earnings targets, contributing to a 2% increase in stock price on the day of the report [2]. Group 2: Market Context - The healthcare sector finished up 12.5% in 2025, with CVS Health being the standout performer amidst concerns regarding regulatory changes under the leadership of RFK Jr. that ultimately did not materialize [1]. - Competitor Walgreens is shutting down many stores, which may provide CVS with a competitive advantage in the market [1].

Group 1 - The core issue is the extreme shortage of the antiviral drug Tamiflu (oseltamivir) in the U.S. and globally, particularly in cold regions facing a severe flu season [1][2] - The American Society of Health-System Pharmacists (ASHP) is urgently assessing the shortage, noting that areas with historically high flu activity are experiencing the most severe supply issues [2] - The CDC reports that hospital visits due to flu-like symptoms have reached the highest level since the 1997-98 flu season, attributed to a new, rapidly spreading flu variant known as subclade K [3] Group 2 - Tamiflu is a neuraminidase inhibitor that reduces the spread of the flu virus and is most effective when taken within 48 hours of symptom onset [4] - The FDA has approved Tamiflu for use in individuals aged 2 weeks and older, with an emphasis on early treatment for high-risk populations [5] - Other commonly prescribed antiviral medications for the flu include zanamivir, peramivir, and baloxavir, each with different mechanisms of action [5] Group 3 - UBS forecasts that the supply shortage of DDR memory products will persist until Q1 2027, with contract prices for DDR products expected to rise significantly [1] - The demand for DDR4 and DDR5 memory is projected to outpace supply growth during this period, with contract pricing expected to increase by 35% in Q4 of this year and by 40% in Q1 2026 [1]

Group 1 - The core issue is the severe shortage of the antiviral drug Tamiflu (oseltamivir) in the U.S. and globally, particularly in cold regions facing high flu activity [1][2] - The American Society of Health-System Pharmacists (ASHP) is assessing the shortage, noting that areas with historically high flu activity are experiencing the most severe supply issues [2] - The CDC reported that hospital visits due to flu-like symptoms have reached the highest level since the 1997-98 flu season, with a notable increase in cases attributed to a new variant of the flu virus [3] Group 2 - Tamiflu is a neuraminidase inhibitor that reduces the spread of the flu virus and is most effective when taken within 48 hours of symptom onset [4] - The FDA has approved Tamiflu for use in individuals aged 2 weeks and older, emphasizing early treatment for high-risk populations [5] - Other antiviral medications listed by the CDC include zanamivir, peramivir, and baloxavir, which have different mechanisms of action [5]

Core Viewpoint - Alpine Income Property Trust, Inc. reported significant investment and disposition activities for Q4 and the full year of 2025, highlighting a strong performance in acquisitions and structured investments, as well as a notable portfolio update [1]. Transaction Activity - In Q4 2025, the Company completed investments totaling $142.1 million with a weighted average initial cash yield of 11.7% [7]. - For the full year 2025, total investments reached $277.7 million, achieving a new annual record with a weighted average initial cash yield of 10.3% [7]. - The Company originated two new structured investments amounting to $33.5 million, both with an initial yield of 12.0% [7]. Dispositions - In Q4 2025, the Company sold five net lease properties for a total of $15.3 million at a weighted average exit cash cap rate of 8.1% [7]. - Full year 2025 disposition activity totaled $82.8 million, including $67.5 million from income-producing asset sales at a weighted average exit cash cap rate of 8.0% [7]. Year-End Portfolio Update - As of December 31, 2025, the Company's property portfolio was 99.4% occupied, with a weighted average remaining lease term of 8.4 years [7]. - 51% of the annualized base rent was attributable to investment grade rated tenants, with Walmart becoming the fourth largest tenant [7].

Group 1 - Most federal and financial institutions, including banks, post offices, and stock markets (NYSE and Nasdaq), will be closed on Christmas Day [2][3] - Major retail companies such as Walmart, Target, Costco, Macy's, and Kohl's will also close their stores for Christmas, giving employees a day off [3] - Select pharmacies like CVS and Walgreens will remain open, but customers should check local store hours as pharmacy counters may be closed [4] Group 2 - Major shipping carriers, including UPS and FedEx, will suspend standard pickup and delivery services on Christmas [2] - Business operations will resume on the following day, Friday, with banks and post offices reopening for regular service [4] - Stock markets will also reopen on Friday and operate during regular trading hours [4]

Core Viewpoint - Investors are encouraged to consider adding dividend stocks to their portfolios for a more consistent income stream, which can be more predictable than pure appreciation investments. The focus should be on companies with solid dividend yields, strong track records, and sufficient earnings or free cash flow to cover and increase dividends [1]. Group 1: Realty Income - Realty Income offers a trailing-12-month dividend yield of approximately 5.62%, making it one of the top dividend-paying companies [3][5]. - The company operates as a triple-net lease REIT, leasing properties to tenants responsible for maintenance, taxes, and insurance, which allows for long-term leases and favorable rates [4]. - Realty Income has a history of paying and increasing dividends for over 30 years, with a compound annual growth rate of 4.2% for its dividends [5][6]. Group 2: Sirius XM - Sirius XM Holdings provides an annual yield of about 5.02%, although its stock performance has not been strong in terms of appreciation [7]. - The company has faced challenges in stabilizing its subscriber base, with a year-over-year decline of about 1% in subscribers at the end of the third quarter [9]. - Warren Buffett's Berkshire Hathaway has acquired a significant stake in Sirius, indicating potential long-term value despite current competition from platforms like Spotify [9].

Core Viewpoint - The article discusses the potential for real estate investment trusts (REITs) to attract investors as interest rates decline, comparing two specific REITs: Realty Income and Vici Properties, to determine which is a better investment for the future [1][2]. Group 1: Overview of Realty Income - Realty Income owns over 15,500 commercial properties primarily leased to recession-resistant retailers, maintaining an occupancy rate of 98.7% in 2024 [4]. - The company has a history of paying monthly dividends and has raised its payout 132 times since its IPO [4]. - Realty's adjusted funds from operations (AFFO) per share grew at a compound annual growth rate (CAGR) of 5% from 2019 to 2024, with expectations of a slight increase in AFFO for 2025 [11][12]. Group 2: Overview of Vici Properties - Vici Properties owns 93 casinos and entertainment properties, focusing on long-term leases with major tenants like Caesar's Entertainment and MGM Resorts, achieving a perfect occupancy rate of 100% since its IPO [6][7]. - The company has raised its dividend annually for seven consecutive years and expects its AFFO per share to rise by 4% to 5% in the near future [7][13]. - Vici's AFFO per share grew at a CAGR of 9% from 2019 to 2024, indicating strong performance despite macroeconomic challenges [13]. Group 3: Comparative Analysis - Both Realty and Vici are triple net lease REITs, requiring them to distribute at least 90% of their taxable income as dividends [3]. - Vici is considered a better investment due to its stronger AFFO growth, perfect occupancy rates, lower valuation, and higher dividends compared to Realty [15]. - As interest rates decline, both companies are expected to benefit from cheaper expansion opportunities and milder macroeconomic headwinds for their tenants [14].

Financial Data and Key Metrics Changes - The company reported a strong fiscal year 2025, with EPS and adjusted operating income both up 16% [4] - The stock price has compounded at 25% over the years, with a 55% increase recently [4] - For fiscal 2026, the company expects operating income growth of 8%-10% on a consolidated basis, with U.S. healthcare operating income growth projected at 9%-11% [5][6] - Long-term operating income guidance has been raised to 6%-9% growth, with EPS growth expectations adjusted to 9%-13% [4][7] Business Line Data and Key Metrics Changes - The company has seen strong pharmaceutical utilization trends and sales of specialty products, contributing to outsized growth [7][8] - The oncology market has been impacted by a competitor acquisition, which is expected to create a 1% headwind, but excluding this, U.S. operating income growth could reach 10%-12% [6][8] Market Data and Key Metrics Changes - The international healthcare solutions segment faced challenges, with 85% of operating income coming from the U.S. and only 15% from international operations [50] - The core distribution business internationally performed well, particularly in the 3PL market, which is the fastest-growing part of the distribution business [51] Company Strategy and Development Direction - The company is focusing on expanding its specialty business and MSO (Managed Service Organization) capabilities, particularly in oncology and retina [8][15] - The strategy includes providing additional management services to physician practices, enhancing operational efficiency [15] - The company aims to maintain a pharmaceutical-centric approach in all strategic moves [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term growth driven by pharmaceutical innovation and demographic trends [9] - There are concerns about potential policy-induced headwinds affecting coverage and insurance enrollment, but management believes pharmaceuticals will remain a critical and efficient form of care [11][12] - The company anticipates continued benefits from biosimilars and generic launches, which are expected to enhance operating income growth [28][30] Other Important Information - The company is committed to balanced capital deployment, with plans for $900 million in capital expenditures, strategic acquisitions, share repurchases, and a 9% increase in dividends [63][64] - The company is evaluating strategic alternatives for underperforming segments, including PharmaLex, while focusing on growth-oriented investments [56][61] Q&A Session Summary Question: What are the key growth drivers for the MSO business? - The MSO business is evolving through organic growth and acquisitions, with a focus on providing higher value services to physician practices [15][17] Question: How does the company view potential headwinds from drug pricing? - The company has historically advocated for community providers and aims to avoid unintended consequences from policy changes that could disrupt access to pharmaceuticals [24][25] Question: What is the impact of biosimilars on the company's revenue and profitability? - Biosimilars are expected to be a tailwind for distribution and GPO, with higher margins compared to brand products [27][28] Question: How is the company addressing challenges in the international market? - The company is focusing on its core distribution business, which has shown strength, while also addressing underperforming segments [50][51] Question: What is the company's approach to capital deployment? - The company prioritizes investments in infrastructure, strategic acquisitions, share repurchases, and dividend growth, maintaining a balanced approach to capital deployment [62][63]

Financial Data and Key Metrics Changes - The company reported a strong fiscal year 2025, with EPS and adjusted operating income both up 16% [4] - The stock price has compounded at 25% over the past several years, with a 55% increase recently [4] - Long-term operating income guidance has been raised to 6%-9% growth, with U.S. healthcare operating income growth expected at 9%-11% for 2026 [4][5] Business Line Data and Key Metrics Changes - The U.S. operating income growth is projected at 9%-11%, with a potential 10%-12% growth when excluding a 1% headwind from a competitor acquisition [5][6] - The specialty business continues to drive outsized growth, particularly in pharmaceutical utilization trends and sales of specialty products [7][8] Market Data and Key Metrics Changes - The international healthcare solutions segment saw weaker performance, with 85% of operating income coming from the U.S. and only 15% from international [50] - The 3PL market is identified as the fastest-growing part of the international distribution business, with improvements noted in the global specialty logistics business [51][53] Company Strategy and Development Direction - The company is focusing on expanding its MSO business, particularly in oncology and retina, to provide higher value services to physician practices [15] - A commitment to remain pharmaceutical-centric in all strategic moves, leveraging innovation in the pharmaceutical market and demographic trends for long-term growth [9][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term growth driven by pharmaceutical innovation and demographics, despite expecting normalization in growth rates post-fiscal 2026 [9][10] - The company is optimistic about the international business for fiscal year 2026, with a turnaround in the global specialty logistics business noted [51][53] Other Important Information - The company plans to invest approximately $900 million in capital expenditures for infrastructure and technology in the current year [62] - A balanced capital deployment strategy includes strategic acquisitions, opportunistic share repurchases, and a commitment to increasing dividends [63][64] Q&A Session Summary Question: What are the key growth drivers for the MSO business? - The MSO business is evolving through organic growth and acquisitions, with a focus on providing management services to physician practices [15][17] Question: How does the company view potential headwinds from drug pricing? - The company has historically advocated for community providers and believes that pharmaceuticals are the most efficient form of care, which should mitigate potential pricing headwinds [24][25] Question: What is the impact of biosimilars on the business? - Biosimilars are expected to benefit the company from a distribution and GPO standpoint, as they offer higher margins compared to brand-name drugs [27][28] Question: How is the relationship with Walgreens affected by its privatization? - The relationship remains strong, with contracts in place until 2029, and the company continues to work on improving operational efficiencies [42][43] Question: What actions are being taken regarding the PharmaLex business? - The company is focusing on the more attractive parts of PharmaLex, particularly in pharmacovigilance, market access, and regulatory affairs, while evaluating strategic alternatives for less competitive segments [56][57]